Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:215135.
doi: 10.1155/2015/215135. Epub 2015 Sep 13.

Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment

Daniela Rizzo  1 , Antonio Ruggiero  1 , Maurizio Martini  2 , Valentina Rizzo  1 , Palma Maurizi  1 , Riccardo Riccardi  1
Affiliations
Review

Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment

Daniela Rizzo et al. Biomed Res Int. 2015.

Abstract

High-grade gliomas are the main cause of death in children with brain tumours. Despite recent advances in cancer therapy, their prognosis remains poor and the treatment is still challenging. To date, surgery followed by radiotherapy and temozolomide is the standard therapy. However, increasing knowledge of glioma biology is starting to impact drug development towards targeted therapies. The identification of agents directed against molecular targets aims at going beyond the traditional therapeutic approach in order to develop a personalized therapy and improve the outcome of pediatric high-grade gliomas. In this paper, we critically review the literature regarding the genetic abnormalities implicated in the pathogenesis of pediatric malignant gliomas and the current development of molecularly targeted therapies. In particular, we analyse the impact of molecular biology on the prognosis and treatment of pediatric high-grade glioma, comparing it to that of adult gliomas.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Molecularly targeted therapy for pediatric malignant glioma.
See this image and copyright information in PMC

References

    1. Faury D., Nantel A., Dunn S. E., et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. Journal of Clinical Oncology. 2007;25(10):1196–1208. doi: 10.1200/JCO.2006.07.8626. - DOI - PubMed
    1. Broniscer A., Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9(2):197–206. doi: 10.1634/theoncologist.9-2-197. - DOI - PubMed
    1. Stupp R., Mason W. P., van den Bent M. J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Cohen K. J., Pollack I. F., Zhou T., et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro-Oncology. 2011;13(3):317–323. doi: 10.1093/neuonc/noq191. - DOI - PMC - PubMed
    1. Lashford L. S., Thiesse P., Jouvet A., et al. Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. Journal of Clinical Oncology. 2002;20(24):4684–4691. doi: 10.1200/JCO.2002.08.141. - DOI - PubMed

Publication types

LinkOut - more resources